Alyeska Investment Group
ALGS icon

Alyeska Investment Group’s Aligos Therapeutics ALGS Stock Holding History

Alyeska Investment Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-244,129
Closed -$5.98M – 562
2024
Q1 		$5.98M Hold
244,129
– – 0.04% 312
2023
Q4 		$4.05M Buy
+244,129
New +$4.2M 0.03% 323

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Alyeska Investment Group's ALGS Position: Q1 2026 in Review

Alyeska Investment Group held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 412,000 shares worth $3.06M. The position accounts for 0.01% of the portfolio, ranked #526.

Alyeska Investment Group first reported a position in ALGS in Q4 2020 and has held it in 9 quarters since. The position peaked at $4.04M in Q3 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Alyeska Investment Group held 412,000 shares of Aligos Therapeutics worth $3.06M as of Q1 2026.
  • Alyeska Investment Group left its Aligos Therapeutics share count unchanged in Q1 2026.
  • Aligos Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #526 holding.
  • Alyeska Investment Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 9 quarters since.
  • Alyeska Investment Group's Aligos Therapeutics position peaked at $4.04M in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.